Premium Nahrungsergänzungsmittel | artgerecht

L12.3 – Epidermolysis Bullosa Acquisita

L12.3 is the ICD-10 code for Epidermolysis bullosa acquisita, a rare autoimmune skin disease causing blister formation.

Regular tips about health Regular tips about health

Things worth knowing about "L12.3"

L12.3 is the ICD-10 code for Epidermolysis bullosa acquisita, a rare autoimmune skin disease causing blister formation.

What is L12.3? – Epidermolysis Bullosa Acquisita

The ICD-10 code L12.3 refers to Epidermolysis bullosa acquisita (EBA), a rare acquired autoimmune disease affecting the skin and mucous membranes. In this condition, the immune system mistakenly produces antibodies that attack the body's own skin structures, leading to pronounced blister formation that can occur spontaneously or following minimal mechanical trauma.

Causes

The disease is triggered by autoantibodies directed against type VII collagen, a key structural protein that anchors the outer skin layer (epidermis) to the inner layer (dermis). When these anchoring structures are damaged, the skin layers separate and blisters form.

The exact triggers of the autoimmune response are not fully understood
A possible genetic predisposition is under investigation
An association with inflammatory bowel diseases (e.g., Crohn's disease) has been described

Symptoms

The hallmark symptoms of epidermolysis bullosa acquisita include:

Blister formation on the skin, commonly at pressure points (hands, feet, elbows, knees)
Wounds and scarring after blisters rupture
Involvement of mucous membranes (mouth, esophagus, eyes, genitals)
Itching and burning sensations
In severe cases: scarring with functional impairment

Diagnosis

Diagnosis requires a combination of clinical examination, laboratory testing, and tissue analysis:

Skin biopsy with direct immunofluorescence to detect antibody deposits at the dermal-epidermal junction
Detection of anti-type VII collagen antibodies in the blood (indirect immunofluorescence, ELISA)
Electron microscopy to precisely localize blister formation
Exclusion of other blistering conditions (e.g., bullous pemphigoid, pemphigus vulgaris)

Treatment

Treatment of epidermolysis bullosa acquisita is complex and depends on disease severity. Since it is an autoimmune disease, immunosuppressive strategies are central:

Corticosteroids (e.g., prednisolone) to suppress the immune response
Dapsone – an antibiotic with anti-inflammatory properties
Colchicine to modulate the inflammatory response
Immunosuppressants such as azathioprine, cyclosporine A, or mycophenolate mofetil
Intravenous immunoglobulins (IVIG) for severe or treatment-resistant cases
Rituximab (anti-CD20 antibody) as a more recent therapeutic option
Wound care and skin management to prevent infections

Prognosis

The condition often follows a chronic course with alternating periods of flares and remission. Complete remission is uncommon. The goals of therapy are to reduce blister formation, minimize scarring, and maintain quality of life. Regular dermatological follow-up is essential.

References

German Institute of Medical Documentation and Information (DIMDI): ICD-10-GM Version 2024, Chapter XII – Diseases of the Skin and Subcutaneous Tissue, L12.3.
Ujiie H et al.: Epidermolysis bullosa acquisita. In: Journal of Dermatology, 2021; 48(8):1128–1138. PubMed PMID: 34028854.
Koga H, Recke A, Izumi K et al.: Autoimmune bullous diseases – clinical features, diagnostic workup and therapy. In: JDDG: Journal of the German Society of Dermatology, 2019.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.